Loading
A chemotherapy-free combination for NUT carcinoma: a BET inhibitor with a CDK4/6 inhibitor, on the reasoning that both act on the MYC-driven growth programme the fusion switches on.
BRD4-NUT keeps MYC and other growth genes switched on; BET inhibition alone gives short responses. This NCI phase 1 study adds abemaciclib, a CDK4/6 inhibitor, to ZEN003694 in patients with NUT carcinoma, advanced breast cancer and other solid tumours, to find a tolerable dose and look for activity. It is recruiting.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZEN-3694, NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), National Cancer Institute (NIH) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag owner-request.
Shares National Cancer Institute (NIH) and the tag owner-request.
Shares ZEN-3694, NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares ZEN-3694, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Abemaciclib, CDK4/6.
Shares Abemaciclib, CDK4/6.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/